Expression patterns of cell markers and immunomodulatory genes, and Model of M2 microglia/macrophage production in GBM.

<p>(A) Heat map representation of statistically significant differentially expressed genes (P<0.05). Spearman correlation was performed between the expression levels of the indicated gene pairs in the cohort (Spearman coefficients are shown as colors corresponding to the scale bar). Gray represents gene combinations without significant correlation. (B) Protein interaction subnetwork based on protein-coding genes and their interacting partners. Nodes represent protein coding genes; links represent physical interactions. Nodes in color indicate enriched biological functions of the proteins. A red line is indicative of fusion; green line—neighborhood evidence; blue line—co-occurrence evidence; purple line—experimental evidence; yellow line—text mining evidence; light blue line—database evidence; black line—co-expression evidence. mRNA expression of genes from (C) were used for PCA analysis, which is represented by 2-dimensional visualization. The symbols represent independent patient data (blue—low risk group; pink—high risk group). PCA projections of the first 2 principal components are shown. Arrows represent individual genes with the points directed at their loading coordinates. (D) Tumor-derived molecules, such as TGFβ and M-CSF, can polarize glioma-associated microglia/microphages (MMs) toward the M2 phenotype and stimulate the production of anti-inflammatory molecules. Other glioma-derived molecules, such as CCL2 and VEGF, can recruit myeloid cells into the tumor site. TAMs refer to tumor-associated microglia/macrophages.</p

Development of the prognostic model.

<p>Kaplan—Meier curves for overall and progression-free survivals in the two groups (low risk and high risk) as defined by a prediction model based on the weighted expression of six genes (CCL2, CCR2, CXCL10, IL10RB, IL17B, and IL17R) (A, B). This Kaplan-Meier assessment of OS and PFS in patients with glioblastoma illustrates a risk score analysis using this signature in the TCGA cohort (C, D). The risk score has prognostic value of survival in the radiotherapy plus temozolomide group from both the CGGA and TCGA datasets (E, F, G, H).</p

Distribution of risk scores and patient survival duration.

<p>Analysis of risk scores, OS, and mRNA expression in the CGGA cohort (A) and the TCGA cohort (B), including (Top) signature risk score distribution and (Middle) patient survival status and duration. A heat map showing expression of the six genes in both the high-risk and low-risk groups (Bottom); rows represent corresponding genes, and columns indicate corresponding patients. The black dotted lines in the middle of each graph (A, B) represent the gene signature cutoff (median risk score). Principal component analyses (C) of the CGGA dataset using the six genes. Graph of the first 3 principal components shows excellent separation between low-risk (pink) and high-risk (blue) groups. PCA1, PCA2, and PCA3 represent the top three dimensions of genes showing differential expression among these preimplantation blastomeres, which account for 41.2%, 17.6%, and 15.6% of the expressed genes, respectively.</p

Clinicopathological characteristics of patients with primary glioblastoma in the CGGA dataset (n = 105).

<p>Clinicopathological characteristics of patients with primary glioblastoma in the CGGA dataset (n = 105).</p

Assessment of gene expression between the high and low subgroups.

<p>The enrichment plots of the immunologic gene expression signatures of activated microglia are separated into high- and low-risk score groups. A, NES = 1.76, p-val<0.05; B, NES = 2.31, p-val<0.001; C, NES = 2.27, p-val<0.001. NES refers to Normalized Enrichment Score; p-val refers to FWER p value. M2 microglia/macrophage markers (CD68, CD163, CD204, and CD206) were significantly up-regulated in the high-risk group (D). MDSC markers (CD11b, CD14, CD15, and CD33) showed increased expression in the high-risk group (E). Genes encoding TGFβ1 and IL10 are expressed at higher levels in the high-risk group (F). M1 markers (iNOS and IL12) are not significantly different between the low-risk group and the high-risk group (G). *, P<0.05; **, P<0.01; ***, P<0.001.</p

Factors associated with OS and PFS in the Cox regression analysis for patients from the CGGA dataset.

<p>Factors associated with OS and PFS in the Cox regression analysis for patients from the CGGA dataset.</p